



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Durvalumab

|           |   |
|-----------|---|
| Cat. No.: | HY-P9919  |
| CAS No.:  | 1428935-60-7  |
| Target:   | PD-1/PD-L1  |
| Pathway:  | Immunology/Inflammation   |
| Storage:  | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

|                                     |  |   |
|-------------------------------------|--|---|
| <b>Description</b>                  | Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody <sup>[1]</sup> . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC <sub>50</sub> s of 0.1 and 0.04 nM, respectively <sup>[2]</sup> .   |   |
| <b>IC<sub>50</sub> &amp; Target</b> | IC <sub>50</sub> : 0.1 nM (PD-L1/PD-1), 0.04 nM (PD-L1/CD80) <sup>[2]</sup>  |   |
| <b>In Vivo</b>                      | <p>Durvalumab inhibits tumor growth in mouse xenograft models of human melanoma (A375) and pancreatic (HPAC) tumour cell lines, via a T-cell-mediated mechanism. Durvalumab (5-0.01 mg/kg for NOD/SCID mice with HPAC tumor; 5-0.1 mg/kg for NOD/SCID mice with A375 tumor; administration i.p.; twice per week; for 3 weeks) significantly inhibits the tumor growth of both HPAC and A375 xenografts compared with an isotype-matched control antibody. Tumor growth inhibition of the HPAC cells reaches 74%, whereas inhibition of the A375 cells reaches 77%. When administered in the absence of T cells, Durvalumab has no effect on the growth of the A375 tumor xenograft<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> |   |
|                                     | Animal Model:  | NOD/SCID mice with HPAC tumor, following coimplantation of primary human T cells; NOD/SCID mice with A375 tumor, following coimplantation of primary human T cells <sup>[2]</sup> |
|                                     | Dosage:  | 5, 1, 0.1, and 0.01 mg/kg for NOD/SCID mice with HPAC tumor; 5, 1, and 0.1 mg/kg for NOD/SCID mice with A375 tumor  |
|                                     | Administration:  | Administration i.p.; twice per week; for 3 weeks  |
|                                     | Result:  | Significantly inhibited the tumor growth of both HPAC and A375 xenografts compared with an isotype-matched control antibody.  |

### CUSTOMER VALIDATION

- Cancer Discov. 2020 Dec;10(12):1872-1893.
- Cell Rep. 2022 Feb 8;38(6):110349.
- Research Square Print. 2022 Aug.

- Preprints. 10 May 2022.
- Patent. US20200253884A1.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

- [1]. Faiena I, et al. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. *Drug Des Devel Ther.* 2018 Jan 23;12:209-215.
- [2]. Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. *Cancer Immunol Res.* 2015 Sep;3(9):1052-62.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA